Literature DB >> 16711003

Influence of ciglitazone on A549 cells growth in vitro and in vivo and mechanism.

Wanguang Zhang1, Huilan Zhang, Lihua Xing.   

Abstract

The effect and mechanism of the ciglitazone on lung cancer cells A549 growth in vitro and in vivo were studied. Various concentrations of ciglitazone were added to the cultured A549 line, and the proliferation and differentiation of A549 cells were examined by MTT and cytometry analysis. A549 cells (1 x 10(6)/mouse) were inoculated subcutaneously into 20 nude mice, which were randomly divided into two groups: the control group, the ciglitazone treated group. The weights of subcutaneous tumors were measured. The expression of cyclin D1 and P21 in the lung was detected by immohistochemistry and Western blot respectively. The results showed that the proliferation of A549 was inhibited significantly by ciglitazone in a dose- and time-dependent manner. There were more cells arrested in G1 /G0 phase and the expression of PPARgamma was markedly up-regulated in ciglitazone-treated group. Direct injection of ciglitazone into A549-induced tumors could suppress tumor growth in nude mice and the growth inhibitory rate was 36%. The expression of cyclin D1 was decreased and P21 increased significantly in ciglitazone-treated group as compared with control group. It was concluded that ciglitazone could inhibit A549 proliferation dose-dependently and time-dependently and induce differentiation, which might be related to the modulation of cell cycle interfered by PPARgamma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16711003     DOI: 10.1007/bf02828033

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  15 in total

Review 1.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.

Authors:  K Schoonjans; B Staels; J Auwerx
Journal:  Biochim Biophys Acta       Date:  1996-07-26

Review 2.  [Peroxisome proliferator-activated receptors-gamma (PPAR-gamma) and their role in immunoregulation and inflammation control].

Authors:  Milena Sokołowska; Marek L Kowalski; Rafał Pawliczak
Journal:  Postepy Hig Med Dosw (Online)       Date:  2005       Impact factor: 0.270

3.  The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers.

Authors:  R N DuBois; R Gupta; J Brockman; B S Reddy; S L Krakow; M A Lazar
Journal:  Carcinogenesis       Date:  1998-01       Impact factor: 4.944

4.  15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells.

Authors:  S B Shappell; R A Gupta; S Manning; R Whitehead; W E Boeglin; C Schneider; T Case; J Price; G S Jack; T M Wheeler; R J Matusik; A R Brash; R N Dubois
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

5.  PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

Authors:  C Jiang; A T Ting; B Seed
Journal:  Nature       Date:  1998-01-01       Impact factor: 49.962

6.  Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells.

Authors:  J A Brockman; R A Gupta; R N Dubois
Journal:  Gastroenterology       Date:  1998-11       Impact factor: 22.682

7.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

Authors:  S A Kliewer; J M Lenhard; T M Willson; I Patel; D C Morris; J M Lehmann
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

8.  Terminal differentiation of human breast cancer through PPAR gamma.

Authors:  E Mueller; P Sarraf; P Tontonoz; R M Evans; K J Martin; M Zhang; C Fletcher; S Singer; B M Spiegelman
Journal:  Mol Cell       Date:  1998-02       Impact factor: 17.970

9.  Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping.

Authors:  M E Greene; B Blumberg; O W McBride; H F Yi; K Kronquist; K Kwan; L Hsieh; G Greene; S D Nimer
Journal:  Gene Expr       Date:  1995

10.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

Authors:  P H Maxwell; G U Dachs; J M Gleadle; L G Nicholls; A L Harris; I J Stratford; O Hankinson; C W Pugh; P J Ratcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

View more
  9 in total

Review 1.  Peroxisome proliferator-activated receptors and cancer: challenges and opportunities.

Authors:  Jihan Youssef; Mostafa Badr
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

2.  Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer.

Authors:  Shou Wei Han; Jesse Roman
Journal:  World J Biol Chem       Date:  2010-03-26

Review 3.  Targeting Nuclear Receptors in Lung Cancer-Novel Therapeutic Prospects.

Authors:  Shailendra Kumar Gangwar; Aviral Kumar; Kenneth Chun-Hong Yap; Sandra Jose; Dey Parama; Gautam Sethi; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-18

4.  Thiazolidinediones as anti-cancer agents.

Authors:  Carmelo Blanquicett; Jesse Roman; C Michael Hart
Journal:  Cancer Ther       Date:  2008

5.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

6.  Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells.

Authors:  Takayuki Yoshizaki; Wataru Motomura; Sachie Tanno; Shima Kumei; Yumiko Yoshizaki; Satoshi Tanno; Toshikatsu Okumura
Journal:  J Exp Clin Cancer Res       Date:  2010-03-10

7.  Heterotrimeric G-protein, Gα16, is a critical downstream effector of non-canonical Wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancer.

Authors:  Sreedevi Avasarala; Rama Kamesh Bikkavilli; Michelle Van Scoyk; Wei Zhang; Ajibike Lapite; Logan Hostetter; Joshua T Byers; Lynn E Heasley; Jang Won Sohn; Robert A Winn
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

8.  Activated PPARgamma Targets Surface and Intracellular Signals That Inhibit the Proliferation of Lung Carcinoma Cells.

Authors:  Shou Wei Han; Jesse Roman
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  Peroxisome proliferator-activated receptors in lung cancer.

Authors:  Venkateshwar G Keshamouni; Shouwei Han; Jesse Roman
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.